Increased D-dimer is associated with disease progression and increased mortality in Turkish COVID-19 patients
Increased D-dimer is associated with disease progression and increased mortality in Turkish COVID-19 patients
Objective: Coagulopathy is thought to play an important role in the development of severe COVID-19. High D-dimer levels have been
reported in Chinese cohort studies. However, ethnicity has significant implications for thrombotic risk. Our aim in this study is to
determine the effect of D-dimer measurements on disease prognosis and mortality in Turkish patients with COVID-19.
Patients and Methods: The study was designed retrospectively. Patients over the age of 18 who were admitted to our hospital were
included in the study.
Results: The study included 226 patients. According to the World Health Organization staging, 75(33.2%) patients, according to the
staging of Siddiqi et al., 67 (29.7%) patients progressed. In the ROC analysis performed to predict mortality, AUC value for D-dimer
was found to be 82.25% (95%CI 74.8%-89.71%). When the cut-off value for D-dimer was accepted as ≥3.25mg/L, specificity was
94.15%, correctly classified rate 88.5%, positive likelihood ratio as (LR):5.69, negative LR:0.71.
Conclusion: As a result, similar to the Chinese cohorts, elevated D-dimer measurements increase disease progression and mortality
in Turkish patients with COVID-19. D-dimer levels of 3.25 mg/L and above, strongly determine the risk of increased mortality in the
Turkish Caucasian ethnic group.
___
- [1] World Health Organization, Director-General’s remarks
at the media briefing, April 14th 2020 Available at: https://
www.who.int/director-general/speeches/detail/who-directorgeneral-
s-remarks-at-the-media-briefing-on-2019-ncov-on-
11-february-2020. Accessed 11.02.2020
- [2] Connors JM, Levy JH. Thromboinflammation and the
hypercoagulability of COVID-19. J Thromb Haemost 2020;
18: 1559-61. doi: 10.1111/jth.14849.
- [3] Magro C, Mulvey JJ, Berlin D, et al. Complement associated
microvascular injury and thrombosis in the pathogenesis of
severe COVID-19 infection: A report of five cases. Transl Res
2020; 220: 1-13. doi: 10.1016/j.trsl.2020.04.007.
- [4] Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J,
Vander Heide RS. Pulmonary and cardiac pathology in
African American patients with COVID-19: an autopsy series
from New Orleans. Lancet Respir Med 2020; 8: 681-6. doi:
10.1016/s2213-2600(20)30243-5.
- [5] Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary
vascular endothelialitis, thrombosis, and angiogenesis in
COVID-19. N Engl J Med 2020; 383: 120-8. doi: 10.1056/
NEJMoa2015432.
- [6] Zhou F, Yu T, Du R, et al. Clinical course and risk factors
for mortality of adult inpatients with COVID-19 in Wuhan,
China: a retrospective cohort study. Lancet 2020; 395: 1054-
62. doi: 10.1016/s0140-6736(20)30566-3.
- [7] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant
treatment is associated with decreased mortality in severe
coronavirus disease 2019 patients with coagulopathy. J
Thromb Haemost 2020; 18: 1094-9. doi: 10.1111/jth.14817.
- [8] Liao S, Woulfe T, Hyder S, Merriman E, Simpson D, Chunilal
S. Incidence of venous thromboembolism in different ethnic
groups: a regional direct comparison study. J Thromb Haemost
2014; 12: 214-9. doi: 10.1111/jth.12464.
- [9] Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID19
coagulopathy in Caucasian patients. Br J Haematol 2020; 189:
1044-9. doi: 10.1111/bjh.16749.
- [10] Republic of Turkey, Ministry of Health Available at: https://
covid19.saglik.gov.tr/TR-66301/covid-19 – rehberi.html.
Accessed on 12.02.2020
- [11] Schünemann HJ, Khabsa J, Solo K, et al. Ventilation
Techniques and risk for transmission of coronavirus disease,
including COVID-19: A living systematic review of multiple
streams of evidence. Ann Intern Med 2020; 173: 204-16. doi:
10.7326/m20-2306.
- [12] Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis
campaign: International Guidelines for Management of Sepsis
and Septic Shock: 2016. Intensive Care Med 2017; 43: 304-77.
doi: 10.1007/s00134.017.4683-6.
- [13] Siddiqi HK, Mehra MR. COVID-19 illness in native and
immunosuppressed states: A clinical-therapeutic staging
proposal. J Heart Lung Transplant 2020; 39: 405-7. doi:
10.1016/j.healun.2020.03.012.
- [14] Marshall JC, Murthy S, Diaz J, et al. A minimal common
outcome measure set for COVID-19 clinical research. Lancet
Infect Dis 2020; 20: e192-e7.
- [15] Talon L, Fourneyron V, Trapani A, Pereira B, Sinegre T, Lebreton
A. Analytical performance of a new immunoturbidimetric
D-dimer assay and comparison with available assays. Res Pract
Thromb Haemost 2022; 6: e12660. doi: 10.1002/rth2.12660.
- [16] Rodelo JR, De la Rosa G, Valencia ML, et al. D-dimer is
a significant prognostic factor in patients with suspected
infection and sepsis. Am J Emerg Med 2012; 30: 1991-9. doi:
10.1016/j.ajem.2012.04.033.
- [17] Yin S, Huang M, Li D, Tang N. Difference of coagulation
features between severe pneumonia induced by SARS-CoV2
and non-SARS-CoV2. J Thromb Thrombolysis 2021; 51:
1107-10. doi: 10.1007/s11239.020.02105-8.
- [18] Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in
COVID-19. Eur Heart J Cardiovasc Pharmacother 2020; 6:
260-1. doi: 10.1093/ehjcvp/pvaa036.
- [19] Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose
anticoagulation with in-hospital survival among hospitalized
patients with COVID-19. J Am Coll Cardiol 2020; 76: 122-4.
doi: 10.1016/j.jacc.2020.05.001.
- [20] Taylor FB, Jr., Toh CH, Hoots WK, Wada H, Levi M. Towards
definition, clinical and laboratory criteria, and a scoring
system for disseminated intravascular coagulation. Thromb
Haemost 2001; 86: 1327-30. 2002/01/31.
- [21] Hunt BJ, Levi M. Re The source of elevated plasma D-dimer
levels in COVID-19 infection. Br J Haematol 2020; 190:
e133-e4. doi: 10.1111/bjh.16907.
- [22] Loscalzo J. The macrophage and fibrinolysis. Semin Thromb
Hemost 1996; 22: 503-6. doi: 10.1055/s-2007-999051.
- [23] White RH. The epidemiology of venous thromboembolism.
Circulation 2003; 107: I4-8. doi: 10.1161/01.
Cir.000.007.8468.11849.66.
- [24] Svensson PJ, Dahlbäck B. Resistance to activated protein C as
a basis for venous thrombosis. N Engl J Med 1994; 330: 517-
22. doi: 10.1056/nejm199.402.243300801.
- [25] Franco RF, Reitsma PH. Genetic risk factors of venous
thrombosis. Hum Genet 2001; 109: 369-84. doi: 10.1007/
s004.390.100593.
- [26] Liem TK, Deloughery TG. First episode and recurrent venous
thromboembolism: who is identifiably at risk? Semin Vasc
Surg 2008; 21: 132-8. doi: 10.1053/j.semvascsurg.2008.05.006.
- [27] Akar N, Akar E, Dalgin G, Sözüöz A, Omürlü K, Cin S.
Frequency of Factor V (1691 G – -> A) mutation in Turkish
population. Thromb Haemost 1997; 78: 1527-8. 1998/01/10.
- [28] Iso H, Folsom AR, Wu KK, et al. Hemostatic variables in
Japanese and Caucasian men. Plasma fibrinogen, factor VIIc,
factor VIIIc, and von Willebrand factor and their relations to
cardiovascular disease risk factors. Am J Epidemiol 1989; 130:
925-34. doi: 10.1093/oxfordjournals.aje.a115425.
- [29] Huang C, Wang Y, Li X, et al. Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet
2020; 395: 497-506. doi: 10.1016/s0140-6736(20)30183-5.
- [30] White RH, Keenan CR. Effects of race and ethnicity on the
incidence of venous thromboembolism. Thromb Res 2009;
123 Suppl 4: S11-7. doi: 10.1016/s0049-3848(09)70136-7.
- [31] Gurumurthy G, Gaddam A, Patel V, Patel RS. Coagulopathy
and hospital outcomes in patients with spontaneous bacterial
peritonitis: a call for action to improve care of inpatients.
Cureus 2020; 12: e8926. doi: 10.7759/cureus.8926.
- [32] Tang N, Li D, Wang X, Sun Z. Abnormal coagulation
parameters are associated with poor prognosis in patients with
novel coronavirus pneumonia. J Thromb Haemost 2020; 18:
844-7. doi: 10.1111/jth.14768.